Despite its potential, cfDNA has several limitations:
Low Abundance: The amount of cfDNA in the bloodstream can be very low, especially in early-stage cancers, making detection challenging. Technical Challenges: High sensitivity and specificity are required to distinguish tumor-derived cfDNA from normal cfDNA, necessitating advanced technologies and methodologies. Interpretation Complexity: The presence of mutations in cfDNA does not always correlate with clinical significance, complicating the interpretation of results.
